
Moderna
OrganizationHeard in 237 episodes across 75 shows since Jan 2026
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It develops RNA therapeutics, especially mRNA vaccines, using messenger RNA to instruct cells to produce proteins that can generate immune responses; its pipeline also includes programs targeting infectious diseases and cancer.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Moderna per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Oct 10 | 0.17‰ | 1 |
| Oct 12 | 0.19‰ | 4 |
| Oct 13 | 0.16‰ | 3 |
| Oct 14 | 0.15‰ | 2 |
| Oct 15 | 0.15‰ | 3 |
| Oct 16 | 0.14‰ | 3 |
| Oct 17 | 0.15‰ | 2 |
| Oct 18 | 0.16‰ | 2 |
| Oct 19 | 0.14‰ | 1 |
| Oct 20 | 0.13‰ | 2 |
| Oct 21 | 0.14‰ | 3 |
| Oct 22 | 0.12‰ | 2 |
| Oct 23 | 0.21‰ | 14 |
| Oct 25 | 0.19‰ | 1 |
| Oct 26 | 0.21‰ | 3 |
| Oct 27 | 0.22‰ | 3 |
| Oct 28 | 0.21‰ | 2 |
| Oct 29 | 0.20‰ | 1 |
| Oct 30 | 0.13‰ | 6 |
| Oct 31 | 0.16‰ | 3 |
| Nov 3 | 0.11‰ | 1 |
| Nov 4 | 0.11‰ | 2 |
| Nov 5 | 0.11‰ | 1 |
| Nov 6 | 0.09‰ | 4 |
| Nov 13 | 0.02‰ | 2 |
| Nov 16 | 0.05‰ | 4 |
| Nov 17 | 0.08‰ | 4 |
| Nov 19 | 0.10‰ | 2 |
| Nov 20 | 0.10‰ | 2 |
| Nov 21 | 0.10‰ | 1 |
Email alert
Email me when Moderna comes up on a podcast
One email a week at most, with the new episodes that mention Moderna. Free, no account needed, unsubscribe in one click.
What experts have said about Moderna
111 statements · 72 positive · 29 negative · 4 mixed · 6 neutral
Moderna and Merck’s neoantigen program leads the pipeline with the most Phase 3 trials.
“they're still clearly ahead in the pipeline. They have the most phase three trials.”
Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton OddsListen at 12:23
The Moderna and Merck program’s primary readout is not expected until 2028.
“this one's still not going to reach its primary readout till 2028.”
Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton OddsListen at 12:30
Moderna’s stock rose from $63 to above $174 in one day.
“Moderna was a $63 stock. The next day, it closed above $174”
Open the episode · NVIDIA Without Jensen, Anthropic IPO Risks & Moderna’s Cancer Vaccine 11/12/26Listen at 28:10
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
237 episodes featuring Moderna, newest first
- Nov 21, 2026
AI Makes HR and Technology Joint Owners of WorkThe HCL Review PodcastNov 21, 2026 - Nov 20, 2026
Nvidia sell-off exposes wider cracks in the AI tradeCNBC's "Fast Money"Nov 20, 2026 - Nov 20, 2026
Tempus bets cancer data can become an AI growth engineAfter EarningsNov 20, 2026 - Nov 19, 2026
Anthropic’s IPO could remake San Francisco’s startup economyMoonshots with Peter DiamandisNov 19, 2026 - Nov 17, 2026
Amazon backs AI expansion as NVIDIA leadership risk tests the tradeHalftime ReportNov 17, 2026 - Nov 17, 2026
Biotech bets meet a pivotal FDA succession fightBioCentury This WeekNov 17, 2026